Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Nordihydroguaiaretic acid inhibits transforming growth factor beta type 1 receptor activity and downstream signaling.

Li F, Pham JD, Anderson MO, Youngren JF.

Eur J Pharmacol. 2009 Aug 15;616(1-3):31-7. doi: 10.1016/j.ejphar.2009.06.012. Epub 2009 Jun 17.

PMID:
19540220
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.

Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID.

Breast Cancer Res Treat. 2005 Nov;94(1):37-46.

PMID:
16142439
[PubMed - indexed for MEDLINE]
3.

Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Kalo E, Buganim Y, Shapira KE, Besserglick H, Goldfinger N, Weisz L, Stambolsky P, Henis YI, Rotter V.

Mol Cell Biol. 2007 Dec;27(23):8228-42. Epub 2007 Sep 17.

PMID:
17875924
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.

Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M.

Cancer Res. 2004 Aug 1;64(15):5200-11.

PMID:
15289325
[PubMed - indexed for MEDLINE]
Free Article
5.

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.

Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M.

Cancer Res. 2004 Nov 1;64(21):7954-61.

PMID:
15520202
[PubMed - indexed for MEDLINE]
Free Article
6.

Nordihydroguaiaretic acid, an antioxidant, inhibits transforming growth factor-beta activity through the inhibition of Smad signaling pathway.

Lee CH, Jang YS, Her SJ, Moon YM, Baek SJ, Eling T.

Exp Cell Res. 2003 Oct 1;289(2):335-41.

PMID:
14499634
[PubMed - indexed for MEDLINE]
7.
8.

Activation of extracellular signal-regulated kinase by TGF-beta1 via TbetaRII and Smad7 dependent mechanisms in human bronchial epithelial BEP2D cells.

Huo YY, Hu YC, He XR, Wang Y, Song BQ, Zhou PK, Zhu MX, Li G, Wu DC.

Cell Biol Toxicol. 2007 Mar;23(2):113-28. Epub 2006 Nov 9.

PMID:
17096210
[PubMed - indexed for MEDLINE]
9.

Lefty inhibits receptor-regulated Smad phosphorylation induced by the activated transforming growth factor-beta receptor.

Ulloa L, Tabibzadeh S.

J Biol Chem. 2001 Jun 15;276(24):21397-404. Epub 2001 Feb 20.

PMID:
11278746
[PubMed - indexed for MEDLINE]
Free Article
10.

Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells.

Bourguignon LY, Singleton PA, Zhu H, Zhou B.

J Biol Chem. 2002 Oct 18;277(42):39703-12. Epub 2002 Jul 26.

PMID:
12145287
[PubMed - indexed for MEDLINE]
Free Article
11.
12.

Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling.

Fanayan S, Firth SM, Baxter RC.

J Biol Chem. 2002 Mar 1;277(9):7255-61. Epub 2001 Dec 18.

PMID:
11751851
[PubMed - indexed for MEDLINE]
Free Article
13.

The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.

Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K, Node M, Imamura T.

Cancer Sci. 2005 Nov;96(11):791-800.

PMID:
16271073
[PubMed - indexed for MEDLINE]
14.

TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.

Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P.

EMBO J. 1997 Sep 1;16(17):5353-62.

PMID:
9311995
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Receptor expression modulates the specificity of transforming growth factor-beta signaling pathways.

Murakami M, Kawachi H, Ogawa K, Nishino Y, Funaba M.

Genes Cells. 2009 Apr;14(4):469-82. doi: 10.1111/j.1365-2443.2009.01283.x.

PMID:
19335617
[PubMed - indexed for MEDLINE]
16.
17.

Transforming growth factor-beta inhibits pulmonary surfactant protein B gene transcription through SMAD3 interactions with NKX2.1 and HNF-3 transcription factors.

Li C, Zhu NL, Tan RC, Ballard PL, Derynck R, Minoo P.

J Biol Chem. 2002 Oct 11;277(41):38399-408. Epub 2002 Aug 2.

PMID:
12161428
[PubMed - indexed for MEDLINE]
Free Article
19.

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS.

Mol Pharmacol. 2002 Jul;62(1):65-74.

PMID:
12065756
[PubMed - indexed for MEDLINE]
Free Article
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk